Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
Key Highlights
- ➤IMAAVY (JNJ) sustained adolescent disease-control improvements through Week 108
- ➤MG-ADL improved 2.88 points and QMG improved 8.25 points at Week 108
- ➤Three of six corticosteroid users reduced doses; one discontinued after two years
- ➤54.6% of HCPs cited fluctuating symptom control for discontinuing prior therapy
- ➤76.4% of prednisone users reduced doses after transitioning to IMAAVY
Expert Statements
Jonathan Strober, Director, Pediatric Neuromuscular Program and Neuromuscular Clinic Sponsored by the MDA
“For adolescents living with generalized myasthenia gravis, unpredictable muscle weakness and symptoms such as eyelid droop and double vision can affect more than physical health; they can disrupt school, friendships and their growing independence.”
Jonathan Strober, Director, Pediatric Neuromuscular Program and Neuromuscular Clinic Sponsored by the MDA
“The two-year Vibrance-MG results are encouraging and add to our growing body of evidence of IMAAVY in adolescents with continued improvements in daily function, muscle strength and reductions in corticosteroid use observed over time.”
David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson
“People living with generalized myasthenia gravis can experience fluctuating symptoms that make sustained disease control an important treatment goal.”
David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson
“The HCP survey findings provide important insight into the factors shaping treatment decisions, with fluctuating symptom control emerging as the leading reason healthcare professionals reported for discontinuing prior therapy.”
David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson
“The broader clinical evidence for IMAAVY across adolescents and adults, including reductions in corticosteroid use, further informs our understanding of the potential for IMAAVY to deliver sustained disease control across a broad population of people living with gMG.”
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) PR Newswire
* New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in anti-AChR+(a) adolescents * Retrospective survey in adults identified fluctuating symptom control as a top driver for discontinuing prior advanced treatment, with most patient outcomes improving after transitioning to IMAAVY * Data among 15 novel abstracts on IMAAVY to be presented at the MGFA Scientific Session during AANEM 2026 SPRING HOUSE, Pa., Sept. 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY(®) (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. These data include two-year results from the Phase 2/3 study in adolescents which demonstrated sustained disease control while on IMAAVY, with patients maintaining improvements in daily function and muscle strength alongside reductions in corticosteroid use.(1) In addition, a retrospective survey of healthcare professionals (HCPs) treating adults with anti-AChR(a )or anti-MuSK(b) antibody-positive gMG provides insight into how fluctuating symptoms and the resulting unmet need for more sustained disease control can drive transitions from one advanced therapy to another.(2)
Get started
Create a free account to read the full story.